Search results
Found 193 matches for
MRC WIMM researchers have developed a new method to quickly identify cancerous cells in babies at risk of leukaemia. The team hope that the new protocol could make rapid testing more accessible for clinical laboratories around the globe.
Psaila Group: Normal and Malignant Megakaryocyte/Platelet Biology
MRC MHU
We are interested in (1) Applying state-of-the-art single cell approaches to study normal and malignant megakaryocyte biology and bone marrow fibrosis, to identify new targets for therapy for patients with myeloproliferative neoplasms; and (2) The role of platelets as biomarkers for early cancer detection.
Mead Group: Haematopoietic Stem Cell Biology
MRC MHU
The Haematopoietic Stem Cell Biology (HSCB) Laboratory is focused on understanding how the normal haematopoietic stem/progenitor hierarchy is disrupted during the development of myeloid malignancies. Our overarching aim is to improve the management of myeloproliferative neoplasms and related conditions through better monitoring and therapeutic targeting of malignant stem cell populations.
Jacobsen Group: Haematopoietic Stem Cell Biology
MRC MHU
Research in the Jacobsen group is focused at unravelling normal and malignant hematopoietic stem and progenitor cell biology at the single cell level.
Patel Group
MRC MHU
We study endogenous DNA damage caused by metabolites and their impact on the function of vertebrate stem cells and the ageing process
Hughes Group: Genome Biology
Centre for Computational Biology MRC MHU
Using genomics, computational and synthetic biology approaches to understand how genes are regulated in health and disease.
Nerlov Group: Hematopoietic Stem Cell Genetics
MRC MHU
Hematopoietic stem cell (HSC) transplantation is the only stem cell therapy in routine clinical use, and it is also the cell type that gives rise to most blood cancers. We use single cell biology and genetics to understand how hematopoietic stem cells normally sustain blood formation, and how this process is altered during ageing and when leukemia develops.
Vyas Group: Normal and Leukaemic Blood Stem/Progenitor Cell Biology
MRC MHU
We aim to understand the fundamental biological processes underlying normal and malignant haematopoiesis and translate this to improve patient outcomes through new rational therapies.
Milne Group: Epigenetics and Gene Regulation in Leukaemia
MRC MHU
Aberrant epigenetic changes are a driving force in many human cancers. The focus of our lab is centred on understanding how epigenetics impacts gene regulation so that this information can potentially be used to develop new therapeutic strategies.
Gibbons Group: ATRX Group
MRC MHU
We are interested in the function of the chromatin remodelling factor ATRX and how mutations in this factor lead to human disease.
Developmental Haematology and Paediatric Leukaemia Group
MRC MHU
We are interested in how the special properties of prenatal stem and progenitor cells provide the permissive cellular context for the development of leukaemia in early childhood. Our particular focus is on leukaemias in children with Down syndrome and the newborn.
de Bruijn Group: Developmental Haematopoiesis
MRC MHU
We study the embryonic origins of blood stem cells with the aim to inform the generation of these cells in culture, and ultimate produce clinically relevant blood stem cells for therapeutic purposes.
Porcher Group: Molecular Dissection of Blood Cell Fate Determination
MRC MHU
We study the developmental origin and trajectory of the blood stem cell lineage, and the transcriptional and epigenetic mechanisms underlying specification of this lineage from mesoderm. We use this information to model development of blood stem cells in vitro for regenerative medicine purposes.